ABBV vs ABT
AbbVie Inc. vs Abbott Laboratories · Updated Sep 25, 2026
ABBV — 13 winsABT — 10 wins
Price Performance
ABBV +20.68%ABT -24.15%
Performance
| ABBV | ABT | |
|---|---|---|
| 1 Month | -0.14% | -12.84% |
| 3 Months | +9.16% | +8.56% |
| 6 Months | +28.71% | -3.61% |
| YTD | +16.16% | -19.21% |
| 1 Year | +19.23% | -25.91% |
| 3 Year | +72.92% | +0.22% |
| 5 Year | +145.58% | -20.61% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | +15.0% | +27.3% | +11.2% | -4.6% | +19.3% | +28.4% | +19.6% | -0.8% | -6.3% | +55.0% | +8.7% | -10.1% |
| ABT | -18.6% | +10.4% | +3.0% | +0.5% | -21.0% | +29.0% | +25.9% | +25.0% | +23.0% | +46.1% | -10.5% | +0.0% |
Valuation
| ABBV | ABT | |
|---|---|---|
| P/E Ratio | 130.15 | 28.19 |
| Forward P/E | 18.84 | 18.67 |
| PEG Ratio | 4.50 | 3.32 |
| P/S Ratio | 7.43 | 3.92 |
| P/B Ratio | 16.96 | 2.68 |
| EV/EBITDA | 31.32 | 19.47 |
Financials
| ABBV | ABT | |
|---|---|---|
| EPS (TTM) | $2.04 | $3.59 |
| Gross Margin | +83.54% | +56.28% |
| Operating Margin | +31.56% | +16.50% |
| Net Margin | +4.66% | +9.65% |
| ROE | +13.23% | +9.50% |
| ROA | +2.67% | +5.07% |
| Debt/Equity | 2.65 | 0.52 |
Growth
| ABBV | ABT | |
|---|---|---|
| Revenue Growth YoY | +12.43% | +7.78% |
| Revenue Growth QoQ | -9.72% | -2.57% |
| EPS Growth YoY | -45.83% | -18.24% |
| EPS Growth QoQ | -61.76% | -39.22% |
Technical
| ABBV | ABT | |
|---|---|---|
| RSI (14) | 62.60 | 32.83 |
| % From 20-Day SMA | +2.17% | -4.08% |
| % From 50-Day SMA | +3.34% | -5.36% |
| % From 200-Day SMA | +15.23% | -3.44% |
| % From 52-Week High | -1.47% | -26.05% |
| % From 52-Week Low | +39.15% | +23.48% |
Analyst Ratings
ABBV
Buy(37 analysts)
Strong SellHoldStrong Buy
Price Target
$287.08
+8.48% upside
ABT
Buy(31 analysts)
Strong SellHoldStrong Buy
Price Target
$121.50
+17.95% upside
Overview
| ABBV | ABT | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Medical - Devices |
| Exchange | NYSE | NYSE |
| Market Cap | $466.43B | $176.83B |
| Shares Outstanding | 1.77B | 1.73B |
| Avg Volume (10D) | 4.19M | 9.61M |
| Dividend Yield | 2.59% | 2.43% |
Frequently Asked Questions
Is ABBV or ABT a better buy right now?
Based on 23 comparable metrics, ABBV leads in 13 categories while ABT leads in 10. ABBV has a consensus analyst rating with 37 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, ABBV or ABT?
Over the past year, ABBV returned +19.23% compared to ABT's -25.91%. In the short term (1 month), ABBV returned -0.14% vs ABT's -12.84%.
Is ABBV or ABT more expensive?
ABBV trades at a P/E of 130.15 compared to ABT's 28.19. On a price-to-sales basis, ABBV trades at 7.43x vs ABT's 3.92x. Forward P/E: ABBV at 18.84 vs ABT at 18.67.
Which stock has higher growth, ABBV or ABT?
ABBV's revenue grew +12.43% year-over-year compared to ABT's +7.78%. EPS growth: ABBV at -45.83% vs ABT at -18.24%.
Do ABBV and ABT pay dividends?
ABBV pays a dividend with a yield of 2.59%. ABT pays a dividend with a yield of 2.43%.
Which stock do analysts prefer, ABBV or ABT?
ABBV has 37 analysts with a target price of $287.08 (+8.48% upside). ABT has 31 analysts with a target of $121.50 (+17.95% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.